On the Horizon: The Synthetic Opioid U-49900.
| Autor: | Alzghari SK; Gulfstream Genomics, Gulfstream Diagnostics., Amin ZM; Thomas J. Long School of Pharmacy & Health Sciences, University of the Pacific., Chau S; School of Pharmacy, Texas Tech University Health Sciences Center., Fleming SW; Reference Health Laboratories, Gulfstream Diagnostics., Cho K; Reference Health Laboratories, Gulfstream Diagnostics., Fung V; Department of Emergency Medicine, Parkland Health and Hospital System, Dallas Texas. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2017 Sep 12; Vol. 9 (9), pp. e1679. Date of Electronic Publication: 2017 Sep 12. |
| DOI: | 10.7759/cureus.1679 |
| Abstrakt: | Synthetic opioid use continues to be a problem in the United States. New designer opioids continue to be released as "research chemicals" by vendors, leading to widespread use and potentially devastating consequences. U-49900 is a new synthetic opioid with limited clinical data available. Herein, we provide an overview of U-49900, the anecdotal accounts of U-49900 use that clinicians need to be made aware of, and a call for the federal government to take immediate action in curtailing the use of U-49900. Competing Interests: The authors have declared financial relationships, which are detailed in the next section. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|